Novartis Receives Priority Review Status For Oral MS Development Compound
Once-daily Gilenia (0.5mg) has the potential to become the first approved oral therapy for the treatment of multiple sclerosis (MS). As a result of this designation, the standard
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.